D. Western Therapeutics Institute (TYO:4576) said sales of a glaucoma and ocular hypertension treatment developed from its research have begun in Malaysia through partner Kowa (TYO:7807), according to a Wednesday filing on the Tokyo Stock Exchange.
The product, GLA-ALPHA Combination Ophthalmic Solution, is a fixed-dose eye drop. It is the first combination treatment of its kind and can be used alongside other therapies.
Kowa has sold the drug in Japan since late 2022, with overseas expansion underway. Sales started in Thailand in July, and approval has also been secured in Singapore.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments